Congrats to Gaurav and Stephen for raising $500m for JP Morgan's debut life sciences venture fund, including undisclosed corporate LPs. https://lnkd.in/ehxigFFn It might be less than the $650m i-bank peer Goldman Sachs raised for West Street Life Sciences I in January but points to an emerging trend for the big financial services firms to finally be taking venture seriously and use their distribution muscle to raise large amounts and put them in the same category as experienced VCs like Foresite Capital that are on their sixth fund (and congrats on raising $900m this week!) It also points to the forthcoming challenge a lot of the independent VCs will face - few folks want to give them money. Pitchbook noted 13% are not planning on raising another fund and Joe at Inc lays out some good reasons why https://lnkd.in/ea9s-7ha But crunch the LP data on the VCs that do raise and raise again and you'll find there's a good indicator for these folks - delighted to share at the www.GCVsymposium.com
Congrats Gaurav Gupta and Stephen Squinto
Translating biotechnology to business transformation, Expert in Innovation & Entrepreneurial Strategy
6moKudos also to Amplitude Ventures closing $263M for a second Precision medicine fund. https://amplitudevc.medium.com/a-new-chapter-in-precision-medicine-announcing-amplitude-venturs-second-fund-2a40591f75e3 I think experienced funds are able to raise well (because of their strong track record). but this is not the case for emerging fund managers.. I see how challenging it is for first-time fund managers to raise globally. Interesting times!